CLEOPATRA Trial in Breast Cancer

In this Phase III trial involving first line treatment of patients with HER-2 positive metastatic breast cancer,  the addition of Pertuzumab (an anti-HER-2 humanized monoclonal antibody that inhibits receptor dimerization) to a combination of Trastuzumab and Docetaxel significantly prolonged progression-free survival, without increase in cardiotoxicity when compared to Trastuzumab and Docetaxel alone. It appears that Pertuzumab complements Trastuzumab in targeting HER-2 receptor.

These findings from the CLEOPATRA trial have demonstrated that comprehensive  HER-2 blockade may result in improved outcomes for patients with breast cancer  over expressing HER-2.

The original article was published in the January 2012  issue of the NEJM.

Leave a Reply

Your email address will not be published. Required fields are marked *